Sponsor: AbbVie, Inc
Sponsor Study ID: M22-574
Study Title: M22-574: Phase 3 ABBV-383 vs Standard Available Treatment in Subjects with RRMM with at Least 2 Prior Lines of Therapies
CTO #: 103991
NCT Number: NCT06158841
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Multiple Myeloma
Study Objectives: To evaluate the efficacy, safety, and tolerability of ABBV-383 administered as monotherapy in adult subjects with RRMM who have received at least 2 prior lines of therapy, including exposure to a PI, an IMiD, and an anti-CD38 mAb.